» Articles » PMID: 7523217

Nonalcoholic Steatohepatitis: an Expanded Clinical Entity

Overview
Specialty Gastroenterology
Date 1994 Oct 1
PMID 7523217
Citations 258
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: In the past, nonalcoholic steatohepatitis has been described mostly in obese women with diabetes. The aim of this study was to describe a series of patients with nonalcoholic steatohepatitis with a different clinical profile.

Methods: The clinical, biochemical, and histological features of 33 patients with nonalcoholic steatohepatitis seen from July 1990 to June 1993 were analyzed.

Results: The mean age was 47 years. All patients were antibody to hepatitis C virus-negative. Nineteen of 33 (58%) were men, 20 of 33 (61%) were nonobese, 26 of 33 (79%) had normal glucose levels, and 26 of 33 (79%) had normal lipid levels. Fourteen of 33 (42%) had normal glucose and lipid levels and were not obese. Thirteen of 33 (39%) had pathological increases in fibrosis, 5 of whom had micronodular cirrhosis. Of these 13 with severe, progressive disease, 8 (62%) were women, 8 (62%) were obese, 4 (31%) were diabetic or had an elevated glucose level, and 3 (23%) had hyperlipidemia. Although serum iron studies (transferrin saturation and ferritin) were abnormal in 18 of 31 (58%), no patient had hemochromatosis.

Conclusions: Nonalcoholic steatohepatitis can be a severe, progressive liver disease leading to the development of cirrhosis. It should no longer be considered a disease predominantly seen in obese women with diabetes.

Citing Articles

The NRF-2/HO-1 Signaling Pathway: A Promising Therapeutic Target for Metabolic Dysfunction-Associated Steatotic Liver Disease.

Li N, Hao L, Li S, Deng J, Yu F, Zhang J J Inflamm Res. 2024; 17:8061-8083.

PMID: 39512865 PMC: 11542495. DOI: 10.2147/JIR.S490418.


Resmetirom: A Systematic Review of the Revolutionizing Approach to Non-alcoholic Steatohepatitis Treatment Focusing on Efficacy, Safety, Cost-Effectiveness, and Impact on Quality of Life.

Bittla P, Paidimarri S, Ayuthu S, Chauhan Y, Saad M, Mirza A Cureus. 2024; 16(9):e69919.

PMID: 39439647 PMC: 11495423. DOI: 10.7759/cureus.69919.


Investigation of cardiovascular risk factors in diabetic and nondiabetic patients with nonalcoholic fatty liver disease.

Barati M, Teimouri A, Feizi A, Iraj B, Karimifar M J Res Med Sci. 2024; 29:51.

PMID: 39403226 PMC: 11472873. DOI: 10.4103/jrms.jrms_830_23.


A functional genomic framework to elucidate novel causal metabolic dysfunction-associated fatty liver disease genes.

Saliba-Gustafsson P, Justesen J, Ranta A, Sharma D, Bielczyk-Maczynska E, Li J Hepatology. 2024; .

PMID: 39190705 PMC: 11865357. DOI: 10.1097/HEP.0000000000001066.


Polyphenols improve non-alcoholic fatty liver disease via gut microbiota: A comprehensive review.

Mohammadhasani K, Fard M, Mottaghi Moghaddam Shahri A, Khorasanchi Z Food Sci Nutr. 2024; 12(8):5341-5356.

PMID: 39139973 PMC: 11317728. DOI: 10.1002/fsn3.4178.